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I surely hope that, by the end of my term as
your president four months hence, I can look
back and say that our staff and institution finds
itself rising to a great place. After a month in
which I've found myself being consumed by
my duties as a member of the Board Ad Hoc
Committee to evaluate the cardiac surgery
exclusive contract arrangement issue, it seems
I've been going around and around and
around, ad nauseum.
The committee has received letters from many
members of our staff. In addition, several of
our physicians have chosen to meet with the
committee to discuss their individual opinions
personally. At the time of this writing, we still
have three more evenings of interviews
scheduled prior to compiling our data,
formulating a report, and providing a
preliminary document to the LVH Board of
Trustees at its next meeting on September 9,
1998. No doubt, this report is being anxiously
awaited by the members of both our medical
staff and the Board of Trustees. Interest in our
situation has been generated across the
Commonwealth and beyond. I assure
everyone that our committee is taking its
charge to deliberate on this matter extremely
seriously. Alice G. Gosfield, Esq., continues to
examine this situation on behalf of our staff.
Hopefully, her opinion will be forthcoming in
the near future as well.
(Continued on Page 2)
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(Continued from Page 1)
In the world of hospital and health system network evolution, a
very significant partnership was announced between the
Children's Hospital of Philadelphia and Lehigh Valley Hospital on
August 12, 1998. A pediatric outpatient specialty medical center,
The Children's Hospital of Philadelphia Specialty Care Center of
the Lehigh Valley, will be developed on the campus of
Muhlenberg Hospital Center in Bethlehem. This facility will be
constructed with funds solely donated by the Foundation of
Muhlenberg Hospital Center and is expected to open in 18
months. An advanced pediatric intensive care unit will open at
Lehigh Valley Hospital, Cedar Crest & 1-78, by January 1, 2000,
as well. Our congratulations to all involved in consummating the
negotiations to bring these specialized and needed services to
our patients here in the valley.
This month, the Third Annual Nile Lites gala will be held on
Saturday, September 19, at Allentown College. The beneficiary
of this event will be the Center for Educational Development and
Support. I hope many of our staff are planning to attend and
enjoy an evening of fellowship.
Finally, I have two mundane reminders: 1) the next General
Medical Staff Meeting will be held on Monday, September 14,
beginning at 5:45 p.m., in the Auditorium; and 2) the Medical Staff
Services Office, including John W. Hart, Vice President; Beth
Martin, Executive Secretary; Janet M. Seifert, Physician Relations
Rep, and myself, has relocated to the second floor of the hospital
adjacent to Radiology Ultrasound and across from the O.R.
Lounges.
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LVH and Children's Hospital of
Philadelphia to Build Pediatric
Outpatient Center & ICU
The Children's Hospital of Philadelphia and Lehigh Valley
Hospital (LVH) announced they will collaborate to develop a
pediatric outpatient specialty medical center and inpatient
intensive care unit, the first of their kind in the area.
The outpatient center, which will be called The Children's Hospital
of Philadelphia Specialty Care Center of the Lehigh Valley, is
anticipated to open within 18 months and will be on the campus of
Muhlenberg Hospital Center (MHC) in Bethlehem. It will house
pediatric and adolescent medicine specialists and offer a range of
services, many of which· are not currently available locally. An
advanced pediatric intensive care unit also will be constructed at
LVH's Cedar Crest & l-781ocation and will begin operations by
January 1, 2000. When completed, the facilities will provide
families living within the Lehigh Valley with easy access to highly
specialized medical care for their children.

So, I thank everyone who has offered to provide me with antivert
during these last dizzying weeks, and I look forward to seeing you
on September 14.

The Children's Hospital of Philadelphia and LVH will work with
community-based primary care physicians and pediatric
specialists, as well as consult with families throughoufthe area, to
plan for the array of services that will be available. The shared
goal is to complement and support existing pediatric services
(allergy, cardiology, general pediatric surgery, neurology,
ophthalmology and pulmonary) and provide new services to the
Lehigh Valley: adolescent medicine, cancer care, child and
adolescent psychiatry, dermatology, developmental pediatrics,
endocrinology/diabetes, genetic counseling, gastrointestinal and
nutrition, nephrology, physical and occupational
therapy/rehabilitation, and rheumatology.

~·

Prior to the center's opening, specialists from The Children's
Hospital of Philadelphia will begin seeing patients this fall at 401
N. 17th Street in Allentown.

Robert X. Murphy, Jr., MD
Medical Staff President

For Your Calendar
*A meeting of the General Medical Staff of Lehigh Valley
Hospital will be held on Monday, September 14, beginning at
5:45p.m., in the hospital's Auditorium at Cedar Crest & 1-78.
All members of the Medical Staff are encouraged to attend.
*A general membership meeting of the Greater Lehigh
Valley Independent Practice Association, Inc., will be held
on Tuesday, September 22, beginning at 6 p.m., in the
hospital's Auditorium at Cedar Crest & 1-78. This session
will include information and discussion regarding the
PennCARE Physician Services Agreement.

"We are extraordinarily pleased that the country's first and
foremost children's hospital has chosen to partner with Lehigh
Valley Hospital," said Elliot J. Sussman, MD, President and Chief
Executive Officer, LVHHN. "This is a major step toward
enhancing the caliber and scope of children's health care services
available right here in our community."
According to Steven M. Altschuler, MD, Physician-in-Chief at The
Children's Hospital of Philadelphia: "Many families we see at the
main campus in Philadelphia are from the Lehigh Valley. To bring
these services to the area will make a difference in the lives of
these families, who before had to drive great distances to get thP
care their pediatricians and physicians believed they needed."
(Continued on Page 3)
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)John D. VanBrakle, MD, Chairperson, Department of
'Pediatrics at LVH, agreed. "More than 1,000 children
and their families travel outside our area each year for
specialized medical care. Parents continually ask that
these services be more convenient. Our goal is to
provide most of the pediatric resources these children
need in a setting closer to their homes and families' place
of work. We believe there will be a tremendous benefit to
all if the pediatric care they need can be provided within
their own community whenever possible," he said.
LVH will construct the outpatient center, which will
connect to the north side of MHC. Construction is
expected to begin next summer. The center will be
between 5,000 to 10,000 sq. ft.
The Children's Hospital of Philadelphia will lease,
operate, and staff the facility. It will work with LVH to
recruit physicians in such pediatric specialties as
oncology and gastrointestinal medicine. These
physicians will live and practice full time in the Lehigh
, Valley. In addition, The Children's Hospital of
)Philadelphia will schedule its own pediatric specialists
based at the Philadelphia hospital to come see area
patients as needed. A small percentage of children with
highly complex medical conditions will be treated at the
Philadelphia location.
The center at Muhlenberg will be modeled after The
Children's Hospital of Philadelphia Specialty Care Center
in Exton, Pa. That center has 14 exam rooms, an
outpatient surgical suite, an audiology suite, a diagnostic
radiology suite, an ophthalmology suite, and a
physical/occupational therapy suite, along with various
testing facilities.
Similar outpatient centers are located in King of Prussia,
Pa., and Vorhees, NJ, with the latest one scheduled to
open in April in Chalfont, Pa.
Pediatricians from LVH will collaborate with The
Children's Hospital of Philadelphia to develop a Level II
pediatric intensive care unit at LVH. This unit has the
)capability to care for severely ill children requiring
hospitalization, including children on ventilators, those
recovering from extensive surgical procedures, and
others requiring continuous bedside nursing care. The

new unit also will be able to stabilize and support a
patient during the critical time before transfer to The
Children's Hospital of Philadelphia should the nature of
the illness require the care of a Levell unit.
The LVH pediatric intensive care unit will be adjacent to
the pediatric inpatient unit and the new neonatal
intensive care unit at Cedar Crest &1-78. It will extend
the capabilities of LVH's Levell Trauma Center, one of
four trauma centers in the state that is also qualified to
treat children with critical injuries.
The Children's Hospital of Philadelphia opened in 1855
as the nation's first children's hospital, and today
provides medical and surgical care to children from
throughout the world. It has been ranked by U.S. News
and World Report as one of America's best pediatric
hospitals for seven years in a row.

On August 17, Patient Access relocated to
the third floor of the 1770 Building on the
Muhlenberg Hospital Center campus.
Patient Access Scheduling Telephone
Number:
(610) 317-4545
Hours of operation:

Monday - Friday- 8 a.m. to 4:30 p.m.
The address to use for U.S. Mail is:
Patient Access
Room 333
1770 Bathgate Drive
Bethlehem, PA 18017
The address for Inter-office mail is:
Patient Access
Room 333
1770 Bathgate
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Shock/Trauma and CNS Merger Set
for September
Fewer inpatients and briefer stays in the Shock/Trauma and
Central Nervous System units have led to the decision to
merge the units on September 9. This will reduce the total
number of beds and staff, and save several million dollars
per year.
The new 12-bed "Trauma/CNS Unit" will occupy the former
shock/trauma (STU) area at Cedar Crest & 1-78, and treat
both trauma and neurosurgery patients. The merged unit
will contain eight fewer beds than the combined total of STU
and-central nervous system (CNS), which have 12 and
eight, respectively. After the merger, the special care unit
will move to the vacant CNS space on the sixth floor.
Clinical work redesign over the past year has significantly
decreased the patient census and length of stay in both
units, said Kate Quinn O'Hara, Administrator for STU and
CNS. "Because of these trends and the expected loss of
trauma patients to a local competitor, we saw an opportunity
to merge the two similar units and improve our overall
costs," she added.
According to Michael D. Pasquale, MD, Chief, Division of
Trauma/Surgical Critical Care, and Medical Director of the
Shock/Trauma Unit, "We're seeing the same number of
trauma patients in the Emergency Department, but
admitting fewer. We don't need as many beds." Dr.
Pasquale and Mark C. Lester, MD, Chief, Division of
Neurological Surgery, have been named co-medical
directors for the merged unit.
The average length of stay for trauma patients is a day
shorter than six months ago, due chiefly to newly devised
clinical protocols that focus on providing the right care in the
right setting, Dr. Pasquale added. "We don't keep blunt
cardiac injury patients for a mandatory 24 hours in
shock/trauma anymore, for example. We do an EKG, and if
it's normal, we discharge the patient."
Likewise, most brain surgery patients, whether being
treated for trauma, cancer or another neurologic condition,
now spend only a day in CNS, down from three to four days
last year, said Carol Fox, RN, CNS Director since 1994,
who will be Patient Care Director of Trauma/CNS.
Shock/Trauma's current Director, Mary Jean Osborne, RN,
calls the merger "a good idea, one whose time has come. •
She is working with Mrs. Fox to prepare for the integration

of the units' staff member committees and reviewing the
educational requirements for the new nursing staff.
"We're changing cultures, which is challenging," Mrs.
Osborne says. "Some of these are long-standing
committees." After the merger, she will assume the patient
care director position in the Open Heart and Transitional
Open Heart units.
All staff will require several months of cross-training before
being able to care for both trauma and neurosurgery
patients, according to Mrs. Fox. "The patients, though
similar, are not identical. Initially, staff will treat the types of
patients they're familiar with, while they develop expertise in
caring for the other types of conditions.
The consolidation will reduce a total of 22 FTEs from both
units. Most staff have been placed in positions on the new
unit, filling vacancies that have been op~n since January.
While staff may have some discomfort or concerns about
the upcoming change, Drs. Pasquale and Lester have
nothing but praise for the planning and people involved.
"The decision-making process has gone smoothly because
it involves nurses, physicians and respiratory therapists," r
Pasquale noted. "The change has been painful for staff, but
they have been truly phenomenal in handling the situation."
Dr. Lester agrees: "They have shown incredible
professionalism and are very committed to the merger.
Mary Jean and Carol have done an impressive job working
with the staff. The merger is a real tribute to their
leadership."

Reminder
When a patient expires, it is the responsibility of
the family/significant other to contact the funeral
director. If a patient does not have any
family/significant other, contact Clinical Resource
Management at 402-8604 for the Discharge
Planner involved with the case. After hours, page
the on-call discharge planner.
It is extremely important that this be
communicated during your interactions with the
family/significant other of the deceased patient as
they may otherwise assume that the hospital will
contact the funeral director.

)
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East Building Update

~regress continues on the East Building.

Structural steel
was completed on June 24, with a "Topping Off'
ceremony on the 25th. All concrete floors are poured,
and piping and ductwork installation continues in the
basement and on the upper floors.

The next major milestone is to cover the building with the
precast concrete and glass "skin". This activity, which will
be accomplished using a crane the same size as the one
used to erect the structural steel, began on August 11
and will take approximately 20 working days. Precast
panels will be placed on the west exposure first and
continue around the front of the building toward the 1210
building. After completion of the north tower, the large
crane will be moved to the south of the facility to continue
erecting the precast. During the later part of August, air
handlers and a boiler were placed onto the penthouse.
In addition, the glass curtainwall will start to appear on
the north facade of the building. This phase should take
about two months to complete.. Plans are to have the
· . entire building enclosed and weathertight by the end of
)he year.
Please be careful when traveling between buildings on
the south side of the facility. Observe all safety signs and
do not enter the construction area without the proper
safety gear.
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Illegible Handwriting
Physicians with illegible handwriting continue to be a
chronic problem in that subsequent caregivers are unable
to decipher orders, notes, etc., and are also unable to
identify the physician's name so that he or she could be
contacted to clarify the documentation.
According to Medical Staff Bylaws, "All orders must be
written clearly, legibly and completely. Orders which are
illegible or improperly written will not be carried out until
rewritten or understood by the nurse. Any practitioner
with non-legible handwriting will be required to print or
stamp his or her full name under his or her signature."
The medical record currently has an "Initial and Signature
Record" (Form # NSG-25) on which other caregivers print
their names and write their signatures. At its October
meeting, the Medical Executive Committee approved the
policy whereby those physicians who are identified as
having illegible handwriting will be required to print their
names and write their signatures on this sheet as well.
When physicians with illegible handwriting are identified,
the Medical Record Committee will make a
recommendation to the Medical Executive Committee to
require those physicians to utilize the "Initial and
Signature Record" on all of their patients medical records.
Furthermore, a letter of warning will be issued from the
Medical Staff President to offenders at the time the
illegible handwriting is identified. Following a six month
review, if illegible handwriting continues, another letter
will be issued requiring the physician to print or stamp
their names after each signature in the record. If a third
six-month review reveals continual illegible handwriting or
failure to utilize the methods outlined above (signature
sheet, rubber stamp, printing name), the physician will be
placed on probation and subject to further corrective
action.
If you have any questions regarding this issue, please
contact Zelda Greene, Director, Medical Records, at
402-8330.

)Above, the large crane hoists one of the large precast panels
to be placed on the outside of the East Building.
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Medical Staff Services Relocates at
Cedar Crest & 1-78
The Office of Medical Staff Services, including John W.
Hart, Vice President; Robert X. Murphy, Jr., MD, Medical
Staff President; Beth Martin, Executive Secretary; and
Janet M. Seifert, Physician Relations Rep., recently
relocated to the second floor of the hospital adjacent to
Radiology Ultrasound and across from the O.R. Lounges.
Telephone numbers for these individuals remain the
same. The main number is 402-8980. The telephone
number for Janet Seifert is 402-8590.
Please note that Rita Mest, Director of Medical Staff
Services, and Karen Fox, Credentialing Technician, will
remain in their present location on the first floor of the
hospital adjacent to the Medical Staff Lounge. Rita's
telephone number is 402-8975; Karen's number is
402-8957.

Page 6

Hospital has one of two recognized programs in the
Lehigh Valley.
Both programs address the educational needs of persons
with type 1 and type 2 diabetes. A physician's referral is
necessary.
The Helwig Diabetes Center provides individual and
group education on a variety of diabetes related topics to
more than 800 patients annually. For more information
about this program, please call (610) 402-9385.
The Northeast Pennsylvania Diabetes in Pregnancy
Program serves over 180 women each year. Services
include preconception counseling for women with
diabetes and education for women with pregnancy
complicated by diabetes, including gestational diabetes.
For more information about this program, please call
(61 0) 402-9511.

You're invited to participate in the
Effective March 1, 1998, Cardiac Rehabilitation
services at LVH can accept patients with U.S.
Healthcare coverage for Phase II cardiac
rehabilitation.

LVH Programs Meet National
Standards
The Pennsylvania Department of Health recently granted
recognition to the Center for Health Promotion and
Disease Prevention's Helwig Diabetes Center and the
Division of Maternal Fetal Medicine's Northeast
Pennsylvania Diabetes in Pregnancy Program.
Recognition is a voluntary process of identifying hospitalbased diabetes outpatient education programs that meet
national standards for diabetes patient education. This is
the third time a three-year term has been awarded to the
programs.
Currently, 85 our of 200 acute care hospitals in
Pennsylvania have recognized programs. Lehigh Valley

6th Annual
Foundation of
Muhlenberg Hospital Center
Golf Classic
Monday, October 5, 1998
Brookside Country Club
Tee Off· 11 a.m.
Golf and sponsorship opportunities are
available. A tennis tournament
will also be held.
Proceeds benefit
Muhlenberg Hospital Center
and
Muhlenberg Rehabilitation Center.
For more information, contact the
Foundation Office at 861-2446.

Medical Staff Progress Notes

September, 1998 X Volume 10, Number 9

Congratulations!
)Gregory R. Harper, MD, PhD, Medical Director of the
John and Dorothy Morgan Cancer Center, has been
appointed as the medical oncology representative on the
Medicare Carrier Advisory Committee for a two-year
term. The Medicare Carrier Advisory Committee
provides a formal mechanism for physicians to participate
in the development of local medical review policy in an
advisory capacity. It also provides a forum for
information exchange and identification of issues
between Xact Medicare Services and members'
constituencies.
Thomas M. Mcloughlin, Jr., MD, Chief, Division of
Cardiac Anesthesia, has received certification in
perioperative tranesophageal echocardiography by
passing the inaugural examination in this discipline
offered by the Society of Cardiovascular
Anesthesiologists and the National Board of
Echocardiography.
In addition, Dr. Mcloughlin has agreed to serve as Guest
)Editor for an upcoming issue of Seminars in
Cardiothoracic and Vascular Anesthesia, published by
W.B. Saunders Company. The journal is a bimonthly
collection of articles focusing on a particular topic in
cardiothoracic or vascular anesthesia. The issue Dr.
McLoughlin will edit is scheduled for publication in
September, 1999, and will focus on "Anesthesia for
Minimally Invasive Cardiac Surgery."

Papers, Publications and
Presentations
A Case Report-- Cardiac Metastasis from Carcinoma of
the Cervix: Report of Two Cases, which was co-authored
by Gazi Abdulhay, MD, Section of Gynecologic
Oncology; Craig J. Sobolewski, MD, Division of Primary
Obstetrics and Gynecology; and Victor R. Risch, MD,
PhD, Chairperson, Department of Radiation Oncology,
was published in the June 1998 issue (Volume 69,
) Number 3) of Gynecologic Oncology.
The May 1998 issue of The Journal of Family Practice
contains several articles co-authored by Will Miller, MD,
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Acting Chairperson, Department of Family Practice. The
articles include "The Value of a Family Physician,"
"Understanding Change in Primary Care Practice Using
Complexity Theory," "Illuminating the 'Black Box': A
Description of 4,454 Patient Visits to 138 Family
Physicians," and "Primary Care Practice Organization
and Preventive Services Delivery: A Qualitative
Analysis." All four of these articles are based on the
direct observation of primary care (DOPC) study, a large
and complex study of the content and processes of family
practice, funded by the National Cancer Institute. DOPC,
based on a multi-method assessment of 4,454 patient
visits to 138 family physicians in 84 practices, is the first
systematic look inside the "black box" of primary care
practice.
JayS. Talsania, MD, Division of Orthopedic
Surgery/Hand Surgery, recently had his article, "Normal
Digital Contribution to Grip Strength Assessed by a
Computerized Digital Dynamometer," published in the
Journal of Hand Surgery (British and European
Volume, 1998) 23B:2:162-166.

Upcoming Seminars, Conferences
and Meetings
Medical Grand Rounds
Medical Grand Rounds are held every Tuesday
beginning at Noon in the hospital's Auditorium at Cedar
Crest & 1-78.
Topics to be discussed in September include:

+ September 8 - Update from the 12th World's
AIDS Conference
+ September 15 - Update on New NSAIDS
including Cyclo-Oxyzenase II Inhibitors
• September 22 - Evaluation & Treatment of
Impotence/Erectile Dysfunction
• September 29 - Special Lecture
For more information, please contact Evalene Patten in
the Department of Medicine at 402-1649.
(Continued on Page 8)
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From the Streets to the Stretcher
From the Streets to the Stretcher, sponsored by the
Emergency Department of Lehigh Valley Hospital, will be
presented on Thursday, October 1, from 7:15a.m. to 5
p.m., at Brookside Country Club of Allentown in
Macungie, Pa.
This program is designed for all professionals related to
emergency care including EMT's, paramedics, physician
assistants, emergency and critical care nurses, and
physicians.
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At the completion of the program, participants should be
able to:
• define the risk factors, symptoms, and signs of heal
and neck cancer
• discuss appropriate diagnostic work-up and
treatment options currently available
• provide multidisciplinary perspective on management
of the head and neck cancer patient
The registration fee is waived for employees and medical
staff affiliated with Lehigh Valley Hospital and Health
Network and Penn CARE.
For more information, please contact Bonnie
Schoeneberger at {610) 402-1210;

Objectives of the program include:
• Describe the critical window of time from onset of
stroke, "Brain Attack," to the initiation of thrombolytic
therapy.
• Identify how the sexual assault nurse examiner,
SANE, program leads to positive patient outcomes.
• Discuss the street smart approach to handling gang
violence encountered by the EMS and in the
emergency department.
• Differentiate between the agreement for and against
euthanasia and the legal implications.
• Explain the i.nsidious course of the Hantavirus
infection and its implications on the Lehigh Valley
• Describe the impact of managed care in the health
care system.
A fee of $85.00 per person includes a continental
breakfast, breaks, lunch, wine and cheese reception, and
all course materials.
For more information, please call Susan Borman at (61 0)
402-1700.

Current Concepts in Head and Neck Cancer
Learn the most recent trends and techniques in the
management of patients with head and neck cancer by
local, regional, and national experts in the field at Current
Concepts in Head and Neck Cancer to be held on
Saturday, October 3, from 7 a.m. to Noon in Conference
Rooms 1A & Bin the John and Dorothy Morgan Cancer
Center.

Who's New at LVH
Medical Staff
Change of Address
Allentown Anesthesia Associates, Inc.
Karen A. Bretz, MD
ln-Ho Chang, MD
J. John Collins, MD
Edgardo S. Cruz, MD
Domenico Falcone, MD
Dorothy I. Hartman, MD
Howard E. Hudson, Jr., MD
JayS. Jung, MD
Serena A. Jung, MD
Jin I. Kim, MD
Samuel M. Lerner, MD
Alphonse A. Maffeo, MD
Thomas M. Mcloughlin, Jr., MD
Carmen B. Montaner, MD
James C. Shaheen, MD
Toeruna S. Widge, MD
Wen-Shiong Yang, MD
1245 S. Cedar Crest Blvd.
Suite 301
Allentown, PA 18103
(61 0) 402·9082
Fax: (610) 402·9029
Tomkin Otolaryngology Associates, PC
Andrew J. Pestcoe, DO
Edward A. Tomkin, DO
311 S. Cedar Crest Blvd.
Allentown, PA 18103

)

)
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News hom.
)

Bed Check System Coming to MHC
Muhlenberg Hospital Center (MHC) is dedicated to improving
patient care and patient outcomes by continually evaluating
and reviewing the standards for patient care and patient
safety. In an effort to increase patient safety and continue to
meet JCAHO standards for providing a "least restrictive"
environment, a Bed Check System will be put into place.
The Bed Check System will be implemented on the inpatient
units at MHC to assist with preventing injury to patients at risk
'}Jf falling out of bed or getting out of bed unassisted. This
system will replace the use of posey vest restraints.
The Bed Check System consists of two components: the
control unit that hangs under the bed, and the disposable
pressure-sensitive sensormat. One cord from the control unit
is plugged into a wall outlet and the other adapted to the
existing call bell system. The sensormat, which is placed
across the width of the bed between the patient and the
mattress, senses whether or not the patient's weight is in the
vicinity of the sensormat and then relays this information to the
control unit. When no weight is on the pad for a preselected
number of seconds, the control unit activates two alarms one is the call bell and the other is an audible alarm in the
patient's room.
Preliminary work to standardize the patient call bell system is
scheduled for early September. Implementation of the Bed
Check System will follow and is targeted for mid-September.
Use of all vest poseys at MHC will be discontinued with the
implementation of the Bed Check System.
This is just one example of the hospital's commitment to
. continuous improvement and quality care for our patients. If
.) you have any questions regarding this change, please contact
Linda Shaffer-Kropf, Critical Care PCS, at 861-4235, or
Sharon Rabuck, Med-Surg PCS, at 861-2413.
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MRI to Offer New Service
In keeping with a long tradition of progress, Muhlenberg
Hospital Center has decided to begin scanning patients with
intracranial aneurysm clips in the MRI suite. Since the early
days of MRI, patients with aneurysm clips in the brain have
been prevented from entering the MRI room or undergoing MR
imaging because of the possibility that the metal clips could
move in the presence of the strong magnetic fields used in
MRI. Overtime, the manufacturers of aneurysm clips
designed for use in the brain have modified the composition of
the clips so that they are constructed of materials that are nonmagnetic or weakly magnetic. Approximately 75% of the
aneurysm clips currently implanted in the United States are
made of these materials. These newer clips are designated
by the manufacturers as MRI compatible, and patients with
these clips can safely be scanned with MRI.
In order to assure the safety of the patient, no patient will be
examined until the pedigree of the clip can be established.
The staff of the MRI center will obtain information about the
implantation procedure and the implanting surgeon. If the
implanting surgeon properly documents the type of clip used,
the clip's manufacturer, and the material the clip is composed
of, and if that clip is listed in the published literature as MRI
compatible, then the patient will be accepted for MRI
scanning.
If the aneurysm surgery was performed at Muhlenberg
Hospital Center, the procedure is less involved. Muhlenberg
Hospital Center is implementing a protocol whereby all of the
aneurysm clips on the implantation tray are designated by the
manufacturer as MRI compatible. Additionally, all of the clips
implanted at Muhlenberg Hospital Center are physically tested
for magnetic compatibility inside a high field 1.5 Tesla scanner
before they are sterilized, adding an extra layer of safety.
It is important to remember that while Muhlenberg Hospital
Center will be scanning certain aneurysm clips, NOT ALL
PATIENTS with intracranial aneurysm clips can have MRI
exams. It is imperative that any patient with an aneurysm clip
in the brain be identified as such immediately so that they can
be properly evaluated. However, if the pedigree of the clip is
well documented as compatible, the benefits of MRI scanning
can be realized by many patients who have previously been
excluded from the MRI department.
If you have any questions or need more information, please
contact John Posh, Chief MRI Technologist, at (610) 6913900.
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Nuclear Medicine Update
Traditionally, thyroid uptake and scan studies performed in the Nuclear Medicine Department have been ordered
together. However, 24-hour uptake and scans may be ordered separately. In order to provide cost-effective care
and to limit radiation exposure (to comply with the ALARA principle), preferred alternatives to thyroid scans are
described below, based on the clinical indication.

CLINICAL INDICATIONS

Solitary or dominant nodule: evaluate function to assess
risk of malignancy.
Solitary nodule: evaluate for multinodularity.

RECOMMENDED PROCEDURE

I Fine-needle aspiration biopsy is a more logical and cost-

I
I

!
\ effective diagnostic approach.
I
i Ultrasonography is a more sensitive approach with no
II
! radiation exposure.
Solitary nodule with equivocal results of fine-needle
i Nuclear thyroid scan is acceptable; 1-123 imaging generally
aspiration biopsy.
i preferable.
Evaluate morphology of multinodular or diffuse goiter.
I Usually no radiology exam in necessary. {Scan results
I
i usually do not influence management.)
Equivocal physical examination results: evaluate for nodule. i Ultrasonography is a more sensitive approach with no
I
i radiation exposure.
I
Evaluate neck mass (? relation to thyroid) or metastatic
i Ultrasonography is a more sensitive approach with no
I
I
cancer unknown primary source. ·
I radiation exposure.
I
)
Evaluate for substernal goiter.
I CT is generally the preferred approach. If nuclear thyroid
i scan is needed, 1-123 generally is preferable.
I
Evaluate for other ectopic thyroid tissue {e.g., lingual) or
Nuclear thyroid scan is acceptable.
exclude that 'thyroglossal duct cyst" is patient's only thyroid
tissue.
Confirm subacute or painless thyroiditis.
I Nuclear thyroid scan gives faster result; 1-123 uptake is less
I costly. Both are acceptable.
Distinguish Plummer's disease from Grave's disease
! Nuclear thyroid scan is acceptable.
'
superimposed on nodular goiter.
I

I

I
I

f

0 CPT 78001 Thyroid Update I CPT 78010 Thyroid Scan I CPT 78007 Thyroid 1-123 Uptake & Scan.
0 A physician's written request is required. A patient referral form may be necessary per some insurance
carriers.
If you have any questions regarding this information, please contact Gregg D. Schubach, MD, Chief, Section of
Nuclear Medicine, Muhlenberg Hospital Center, at (610} 861-2231.

)
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Who's New at MHC

~edical Staff
Appointments
Eugene Alexandrin, MD
Health Network Laboratories
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2260
Department of Pathology
Section of Pathology
Provisional Active
Serhat M. Azizlerli, MD
Nephrology/Hypertension Associates of the Lehigh Valley
Allentown Medical Center
401 N. 17th Street
Suite 212
Allentown, PA 18104-5050
(610} 432-8488
Fax: (610} 258-2140
~partment of Medicine
Section of Nephrology
Provisional Active
Kenneth A. Bernhard, MD
Lehigh Valley Cardiology Associates
2597 Schoenersville Road
Suite 202
Bethlehem, PA 18017-7396
(610) 866-2233
Fax: (610} 866-7738
Department of Medicine
Section of Cardiology
Provisional Active
William F. Bond, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610} 861-2521
Fax: {610} 861-7783
Department of Emergency Medicine
. Section of Emergency Medicine
)rovisional Active

Bala B. Carver, MD
Health Network Laboratories
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610} 861-2260
Department of Pathology
Section of Pathology
Provisional Active
Elizabeth A. Dellers, MD
Health Network Laboratories
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610} 861-2260
Department of Pathology
Section of Pathology
Provisional Active
Jerome C. Deutsch, DO
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610} 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active
Adam D. Dratch, MD
Lehigh Valley Nephrology Associates
701 Ostrum Street
Suite 304
Bethlehem, PA 18015-1155
(610} 865-5888
Fax: (610} 865-1697
Department of Medicine
Section of Nephrology
Provisional Active
Joseph J. Fassl, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610} 861-2521
Fax: (610} 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active
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Stephen P. Fooskas, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

Brian A. Nester, DO
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

Stephen K. Klasko, MD
Center for Woman's Medicine
Lehigh Valley Hospital
17th &Chew, P.O. Box 7017
Allentown, PA 18105-7017
(610) 402-2890
Fax: (610) 402-9688
Department of Surgery
Section of Gynecology
Provisional Courtesy

David M. Richardson, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

Kaushik Kundu, MD
Fabio L. Darville, MD, FACP
1130 Delaware Avenue
Bethlehem, PA 18015
(610} 868-2710
Fax: (610) 868-6130
Department of Medicine
Section of Internal Medicine
Provisional Active

Caren C. Ruht, DMD
Dr. Caren C. Ruht
744 N. 19th Street
Allentown, PA 18104
(610) 776-7770
Fax: (610) 776-6953
Department of Surgery
Section of Dentistry
Provisional Courtesy

Lori A Lawson, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610} 861-2521
Fax: (610} 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

Matthew R. Runde, MD
Lisa S. Bunin, MD
Liberty Square Medical Center
501 N. 17th Street, Suite 213
Allentown, PA 18104-5016
(610) 435-5333
Fax: (61 0} 820-8688
Department of Surgery
Section of Ophthalmology
Provisional Courtesy

James G. McHugh, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

Robert S. Sacchi, MD
Progressive Physician Associates, Inc.
3735 Nazareth Road
Suite 206
Easton, PA 18045-8751
(610) 252-8281
Fax: (610) 253-5321
Department of Radiology
Section of Radiology
Provisional Active
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Diane M. Saldukas-Mazur, MD
LVPG-Emergency Medicine
)Muhlenberg Hospital Center
·2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

William E. Zajdel, DO
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(61 0) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

Luis A. Tejada, MD
Valley Cardiology Associates
701 Ostrum Street
Suite 502
Bethlehem, PA 18015
(610) 861-0377
Fax: (610) 861-7358
Department of Medicine
Section of Cardiology
Provisional Active

Appointment to Leadership Position

William E. Tucker, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
-t545 Schoenersville Road
JBethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active
Anthony T. Werhun, MD
LVPG-Emergency Medicine
Muhlenberg Hospital Center
2545 Schoenersville Road
Bethlehem, PA 18017-7384
(610) 861-2521
Fax: (610) 861-7783
Department of Emergency Medicine
Section of Emergency Medicine
Provisional Active

)
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Gregg D. Schubach, MD
Chief, Section of Nuclear Medicine

Resignations
F. Geoffrey Toonder, MD
Department of Surgery
Section of Thoracic Surgery
Courtesy
John B. Weigele, MD
Department of Radiology
Section of Radiology
Provisional Active

A meeting of the General Medical Staff of
Muhlenberg Hospital Center will be held
on Monday, September 21, beginning at
6:30p.m., in the hospital's cafeteria. All
members of the medical staff are
encouraged to attend.

)

)

)
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You'Ve Waited Patlentlv -- Now lfs Here ...

-,

)

Digital Phone Service
Exclusive to Lehigh Valley Hospital and Health Network -- Lehigh Valley Hospital and
Muhlenberg Hospital Center employees and physicians - Cellular One now offers a unique
digital phone service program.
Digital service offers the power of unmatched voice quality together with extensive coverage,
extended battery life, and calling features to help you manage your time.

Digital Paekage Features:

)

•
•
•
•
•
•
•
•
•
•

First Incoming Minute Free
Calt•r/D'
Basic Voice Mail
Message Notification
Call Waiting
Call Forwarding
Three Party Conferencing
Call Transfer
Activation fee • $25.00 (waived)
NewLower Monthly Access fee - $9.95
• One Low per minute rate • .25
• Largest Digital Coverage in Pennsylvania (see m~p on reverse side)
• Reduced Roaming Rate for the Jersey Shore areas of .49 per minute
This package is available exclusively to Lehigh Valley Hospital and Muhlenberg Hospital Center
employees and physicians with the purchase of a Cellular One digital phone. Phones range from
$129.00 to $199.00.
For more information reg~rding this new service, please contact Gail Keinert at Health Page at (61 0)
402-1811, or Tiffany Noll at Cellular One at (610) 704-1014.

)

LEiiJS!YAIUX
HOSPITAL

LEH~-..-1-l()SPlrfA.l, A.Nl)
1-lE:Al~l·'l·l NF~ri~WOR.I(

Dig.ital Coverage Area
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CARDIAC TROPONIN I
Cardiac Troponin I (cTnl) is a tissue damage marker with absolute specificity for cardiac damage. To date,
no origin for cTnl has been found other than the heart.

Biochemical assessment of tissue damage relies heavily upon markers of intracellular origin. When tissues are
damaged on the cellular level, the cell membranes often loose their integrity. This loss of membrane integrity
allows intracellular substances such as enzymes and polypeptides to leak into the bloodstream. Detection of
increased serum amounts of intracellular components serves as a powerful indicator of tissue (cellular) damage.
Furthermore, since the maintenance of cellular structure relies heavily upon oxygen dependent chemical reactions,
the appearance of intracellular Cardiac Troponin I (cTnl) and Creatine Kinase (CK) serves as powerful indicators of
cardiac oxygen deprivation resulting from ischemia.
Production of proteins and polypeptides ''from" DNA is under the localized control of each cell type. Thus, it is not
surprising to find that different tissues can make different proteins characteristic of each tissue. This is the case for
Troponin I, a small protein component of muscle tissues. Skeletal muscle makes one type of Troponin I while
cardiac Troponin I, cTnl, has been found in NO tissues other than the heart. The gene for cTnl is expressed in no
other tissues. Increased levels of cTnl are absolutely specific indicators of cardiac muscle damage. This is in
contrast to CK, where heart muscle is relatively rich in isoenzyme MCKMB but where MCKMB is also found in other
tissues. cTnl is a specific marker for cardiac damage, but MCKMB is not.

)

Health Network Laboratories has performed analyses for cTnl for some time. Now, our continuing efforts to
improve on the delivery of information about your patients has lead us to adopt a new analytical procedure for cTnl.
Beginning August 10, we began using the Abbott AxSym for the analysis of both cTnl and MCKMB. Our ability to
provide timely information is expected to be better.
New reference ranges for cTnl and MCKMB are found with the new method. These changes appear to result from
a lack of calibration standardization across the industry, not from antibody (method) specificity. Our new values are
as follows:
For Troponin I we found that AxSYM = 3.5 X Stratus- 0.47 with a correlation coefficient of 0.98 for the range of
AxSYM data of 0 - 22 ng/ml.
Troponin I

Normal:

0.0- 0.4 ng/ml

Gray Zone:

Values from 0.5 - 2.0 ng/ml are not "normal" and may indicate a myocardial event
with unstable angina with subsequent risk for an AMI

Elevated:

> 2.0 ng/ml, consistent with an AMI

For MCKMB we found that AxSYM = 1.2 X Stratus + 1.4 with a correlation coefficient of 0.98 for AxSYM values
< 30.0 ng/ml.

MCKMB

)

Normal:

0.0- 10.4 ng/ml

Elevated:

> 10.4 ng/ml, consistent with an AMI
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RELATIVE INDEX:
. MCKMB +Total CK. We will continue our current practice of defining the "cutoff' value as MCKMB cutoff+ mean
of CK male normal. The new cutoff value is 9.2. See the "Cardiac Profile Interpretation Chart".

)

Any questions can be addressed to Dr. Norman Coffman, Technical Director, HNL at Ext. 8219, Tuesdays and
Wednesdays or Dolores Benner, Manager Automation at Ext. 8177.
Clinical data from studies conducted by the manufacturer indicate that, with a cutoff value of 2.0 ng/ml, cTnl has a
sensitivity of 93.9% and a specificity of 93.4% for AMI. A patient was considered positive if any one of the serial
specimens drawn within 24 hours of the onset of chest pain or of presentation at the medical center was elevated.

Norman Coffman, Ph.D.
Technical Director, HNL

D.G. Beckwith, Ph.D.
Clinical Director, HNL

John J. Shane, MD
Medical Director, HNL

CARDIAC PROFILE INTERPRETATION ON SEQUENTIAL SAMPLES
INTERPRETATION
OF RESULT

TOTALCK
(U\L)

Consistent with nonMl condition

Male: 55-170
Female: 30-135

Consistent with
Skeletal Muscle lnj

Increased

MCKMB
(nglml)
~10.4

RELATIVE INDEX
(%) *

TROPONIN I
(ng/ml)

< 9.2

< 0.4

<or> 10.4

< 9.2

< 0.4

Consistent with MI

NORMoriNCR

>10.4

> 9.2

> 2.0

Suggests
Myocardial Ischemia

NORMoriNCR

<or> 10.4

< 9.2

0.5-2.0

)

*Relative Index(%)= 100 X (MCKMBfrotal CK)
Interpretation should consider the serial presentation of results from all three specimens.

)
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Notes from Transfusion
Medicine: Solvent Detergent
Plasma (S/DP) vs. Donor
Retested Plasma
S/DP (Solvent/Detergent Plasma) was
licensed for use in the United States on
June 6, 1998. American Red Cross
(ARC) has been granted exclusive rights to
market this component in the U.S. This
component is being marketed as an
alternative to fresh frozen plasma (FFP).

)

This blood component is prepared from a
pool of 2,500 units of plasma. This pool is
treated with the solvent tri-(N-butyl)
phosphate and detergent (triton-X100)
which inactivates lipid enveloped viruses
including Hepatitis Band C, and HIV. It
has no effect on the non-envelope viruses
such as Parvovirus B19 and Hepatitis A
virus. It has no effect on prions of CJD,
if indeed these can be transmitted by blood
transfusions. Additionally, the effect of
this on yet unknown viral infections which
may be transmitted by transfusion is
unknown.
Aside from the inability of SD Plasma to
inactivate non-lipid envelope viruses as
well as possibilities of short supplies in the
future, because of a single supplier, the
major concern with this component is that
it is prepared from a large pool "2,500
units of donor plasma. " The current
estimated risk for viral transmission on a
per-unit basis is approximately 1 in
670,000 for HIV, 1 in 80,000 for Hepatitis
B, 1 in 30,000 for Hepatitis C and 1 in
4,000 for Parvovirus Bl9. The S/DP will
be available in a fixed volume of 200cc
packaged following the treatment with
solvent detergent.

)

Parvovirus B19 causes a mild viral
exanthem in immunocompetent individuals

with normal bone marrow functions.
However, in patients who are
immunocompromised or have accelerated
bone marrow kinetics it can be associated
with aplastic anemia.
Community blood centers, like Miller
Memorial Blood Center, in the United
States have developed an alternative
product called donor-retested fresh frozen
plasma or delayed release fresh frozen
plasma (FFP-DR). This component is not
currently approved by the FDA (approval
is anticipated in the near future.) This
component is obtained from volunteer
donors. The "standard" FFP is held in
quarantine beyond the estimated infectious
"window period" for the currently
recognized transfusion associated viral
pathogens until the donor returns, is
retested and found to be negative by all
required tests.
Currently, the quarantine period is
estimated to be 112 days. Component is
not pooled and has a standard volume
which varies from 200 to 300cc. The
advantages of FFP-DR are straight
forward: 1) By using only individual
blood donors and maintaining FFP in
quarantine beyond current estimates of the
period when infectious diseases can be
reliably ruled out, the transmission of the
HIV, HCV, HTLV and HBV should be
minimized. 2) As a single donor derived
product the disadvantages of the large pool
plasma are not an issue. The recipient is
exposed to only a single donor and not to
a component prepared for a pool of 2,500
donors. 3) The cost of the FFP-DR will
be only those of assuring appropriate
segregation and storage of quarantine
(estimated cost $85.00 per unit) products.
This is in contrast to the high cost of SD
plasma which is estimated to be
approximately $125.00 unit (200cc) as
compared to the current cost of FFP of
less than $50.00.
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Comparison of 2 components below:
Characteristic

Solvent
Detergent Plasma
(pooled)

Yes

Yes

Contains all labile and stable clotting
factors

Fresh Frozen Plasma Donor
Retested (single donor)

Yes (is FFP)

Can substitute for Fresh Frozen
Plasma

Yes

Chemically treated

Yes

No

Donor Retested Delayed Release for
HIV, HBV & HCV

No

Yes

Pooled product

Yes (2,500 donors)

No (single donor)

Virtually eliminates risk of lllV,
HBV & HCV transmission

Yes

Yes

Decreased risk for unknown lipid
enveloped viruses

Yes

No

Increased risk for unknown non-lipid
enveloped viruses

Yes

No

Dose

200mL

Up to 275 mL

Costs to patients/payers

$125.00

$85.00

The use of SD plasma would have a major
fmancial impact on the cost of providing
fresh frozen plasma in our institution.
Lehigh Valley Hospital uses 7,000
components of fresh frozen plasma a
year. Using only packs of SD plasma
available in 200cc will increase the
numbers of units transfused. After
analysis of the two components, the
Therapeutics Committee recommended and
approved using the Donor Retested Fresh
Frozen Plasma.
We are assessing the appropriateness of
blood usage in L VB, by performing
audits

-c

)

in patient care units. As a result of
these audits, we feel that the initial use
of FFP in most clinical situation is
appropriate, but the follow-up usage
may be amenable to an educational
process, especially for the housestaff.
This involves normalization of INR in
patients who are clinically stable several
days post-op and not experiencing any
bleeding. Therefore we request the
prudent use of blood products.
Please contact Dr. Bala Carver, Medical
Director/Lab-Blood Bank at Ext. 8142
with any questions.

)
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) THERAPEUTICS AT A GLANCE
The following actions were taken at the May- July, 1998 Therapeutics Committee Meeting- Maria Barr, Pharm.D., BCPS,
Rebecca Hockman, Phann.D., BCPS, Joseph Ottinger, R.Ph., MS, MBA, Monica Yost, Phann.D.

Prevacid: L VH & MHC
Prefe"ed PPI
The Therapeutics Committee with the support of
the Division of Gastroenterology has unanimously
approved the replacement of omeprazole
O'rilosec~B - Astra Merck) with lansoprazole
(Prevacid® - Tap Pharm) to the LVH formulary
based on safety efficacy, and cost. Prevacid is on
· the Group Purchasing contract for L VH and
MHC.
Available since 1989, proton pump inhibitors
(PPn are a class of drugs used extensively for a
variety of gastric acid diseases including those
associated with H. Pylori. Currently, this class is
) comprised of only two agents: lansoprazole and
'
omeprazole with a third agent on the way.
Review of these agents reveals that both agents
are similar with respect to FDA labeled efficacy
and safety. Neither agent is approved for use in
pediatrics, however, anecdotal information is
available regarding dosing for omeprazole. As a
result, omeprazole will remain on formulary for
this population until further information is
available.

)

Lansoprazole is available in 15mg and 30mg
extended-release capsules in which the dosage
regimen is dependent on the treatment diagnosis.
The onset of action ranges between 1-3 hours,
appears to be dose-dependent and is affected by
food. Lansoprazole administration is flexible
offering oral, sprinkle, and NG routes, however,
it should be taken on empty stomach or 30
minutes prior to meals to achieve desired effects.
For NG administration lansoprazole should be
opened and the intact granules mixed in 40ml
apple juice to maintain the integrity of the
granules with an acidic pH and administered
through the tube. Additional apple juice should
be used as a flush to clear the tube.

Although lansoprazole undergoes metabolism via
the CYP-450 3A4/2C9 system, it does not appear
to interact with drugs such as the
benzodiazepines, phenytoin, warfarin, digoxin,
and nifedipine which have been documented with
omeprazole. Caution should be taken when
prescribing lansoprazole in combination with
theophylline since patients taking both agents may
experience decreased theophylline levels and
require dosage adjustments. Administration with
sucralfate (Carafate~B) should be separated by 30
minutes to avoid a potential drug interaction.
Both lansoprazole and omeprazole have admirable
safety proflies where headache (7%), diarrhea
(3%), and abdominal pain (2%) are the most
frequently encountered side-effects.
A Therapeutic Substitution of omeprazole to
lansoprazole will result in a cost-savings for
LVH. A summary of LVH and MHC average
outpatient costs per day is represented in Table 1
below.
TABLE 1
Cost Analysis

LVHIMHC
Cost/Day

Outpatient
cost/month*

lansoprazole 15mg
30mg

$2.64
$2.64

$111.27
$110.27

omeprazole

$2.81
$3.13
$4.93

$110.72
$116.87
$199.99

10mg
20mg
40mg

*Average Cash Cost of 1 month supply without
discount obtained from 6 area retail pharmacies.

Uninhibited Choice for
Angiotensin II Receptor
Inhibitors:
The Therapeutics Committee has deferred any
Formulary decisions regarding this relatively new
class of drugs. Therefore, all three currently
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approved agents (Avapro®, Cozaar® and Diovan®)
will be available for patient treatment regimens
until more comparative data is available and
competitive pricing is submitted.
Indicators: All three agents have an FDA
approved indication for treatment of hypertension.
Studies related to their use in adjunctive treatment
of CHF are ongoing.
Mechanism Of Action: Angiotensin II is formed
from angiotensin I in a reaction catalyzed by
angiotensin-converting enzyme (ACE).
Angiotensin II is the principal agent of the reninangiotensin system, with effects that include
· vasoconstriction, acceleration of synthesis and
release ·of aldosterone, cardiac stimulation, and
renal reabsorption of sodium. All three agents
block the vasoconstrictor and aldosteronesecreting effects of angiotensin II by selectively
blocking the binding of angiotensin II to the AT
·receptor in many tissues, such as vascular smooth
muscle and the adrenal gland. Its action is
therefore independent of the pathways for
angiotensin II synthesis.
Blockade of the renin-angiotensin system is also
accomplished via use of the ACE inhibitors,
which inhibit the biosynthesis of angiotensin II
from angiotensin I. Additionally, ACE inhibitors
inhibit the degradation of bradykinin, a reaction
also catalyzed by angiotensin converting enzyme.
Because the Angiotensin Receptor Inhibitors
(ARB) do not inhibit this specific enzyme, they
do not affect the response to bradykinin. Whether
this difference has any clinical relevance is not
,.
yet known.
Drug Interactions:
(lrbesartan)- No significant drug interactions
were found with hydrochlorothiazide, digoxin,
warfarin and nifedipine. In vitro studies show a
significant inhibition of the formation of
irbesartan
metabolites by the CYP2C9 inhibitors;
sulphaphenazole, tolbutamide and nifedipine but
the pharmacokinetics of irbesartan were not
effected by co-administration of nifedipine.

(Losartan)- The pharmacokinetics or
)
pharmacodynamics of warfarin,
hydrochlorthiazide and digoxin were not affected
when co-administered with losartan.
Coadministration with cimetidine led to an
increase of about 18% in AUC of losartan but did
not affect the pharmacokinetics of its active
metabolite. Coadministration of losartan and
phenobarbital led to reduction of about 20% in
the AUC of losartan and that of its active
metabolite. The level of significance of the
cimetidine and phenobarbital interactions is
considered to be minimal. Potent inhibitors of
cytochrome P450 3A4 and 2C9 have not been
studied clinically, but in vitro studies show
significant inhibition of the formation of the active
metabolite by inhibitors of P450 3A4
(ketoconazole, troleandomycin) or P450 2C9
(sulphaphenazole). The pharmacodynamic
consequences of concomitant use of losartan and
these inhibitors have not been examined.
(Valsartan)- No clinically significant
)
pharmacokinetic interactions were observed when
valsartan was coadministered with amlodipine,
atenolol, cimetidine, digoxin, furosemide,
hydrochlorothiazide, or indomethicin. The
valsartan-atenolol combination was more
antihypertensive than either component, but it did
not lower the heart rate more than atenolol alone.
Coadministration of valsartan and warfarin did not
change the pharmacokinetics of valsartan or the
time-course of the anticoagulant properties of
warfarin. The enzymes responsible for valsartan
metabolism has not been identified but do not
seem to be CYP 450 isoenzymes.
Adverse Drug Reactions to body:
All agents have similar profiles and include
dizziness, headache, and fatigue. These agents
should be discontinued if the patient becomes
pregnant.
Please, refer to the comparison chart that
accompanies this article for further informati<
regarding these products.

)

Angiotensin ll Receptor Antagonist Comparison
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)

)

Zocor Rejoins Lipitor
In February, the Therapeutics Committee voted to
carry atorvastatin (Lipitor®) as our sole HMGCoA Reductase inhibitor of choice at LVH.
Please refer to the April, 1998, Medical Staff
Progress News for background data on the
comparison of "statins." This decision was based
on both the efficacy and side effect profile.

)

Due to overwhelming prescribing of simvastatin
(Zocor®) in the community and lack of published
head-to-head comparisons of these agents,
numerous physicians requested the readdition of
simvastatin to the LVH formulary. Also, there
was a significant decrease in cost of simvastatin
for hospital patients. Based on the present
prescribing habits, it was felt that both agents
were needed to be maintained on the LVH
formulary. As a result, atorvastatin will remain
on formulary and be dispensed as written.
Additionally, simvastatin will be available for
LVH prescribers and will be utilized via a

therapeutic substitution for all other "statins"
marketed.
A review of all statins will occur in the future
once the results of the present ongoing study
comparing simvastatin vs. atorvastatin are
available. Until more data is known, both agents
will remain on formulary. Please refer to the
Therapeutics Equivalent Substitution list located in
the hospital formulary Section 4, Appendix XIV
for other statin equivalencies.

Patients on Propulsid?
On June 26, 1998, the News Media succeeded
again! Taken from information printed in the
"FDA talk Paper", the news reported the revised
package labeling that has been issued by Janssen
Pharmaceuticals regarding their product cisapride
(Propulsid®).
Changes in the labeling involve the following: 1)
addition of drugs with known potential to interact,
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2) specification of disease states where use is
CONTRAINDICATED, 3) PRECAUTIONS
regarding use in the PEDIATRIC population, 4)
recommendations for dosage adjustments in
patients with hepatic insufficiency. All of these
changes are to decrease the risk potential for fatal
cardiac arrhythmias including VT, VF, torsades
de pointes, and QT prolongation known to occur
with cisapride.
Several new medications including Serzone,
Crixivan, and Norvir have been identified to
interact with cisapride. These and all other
agents that are metabolized via the CYP-450 3A4
pathway have the potential to increase serum
concentrations of cisapride and should be avoided.
Also, drugs known to prolong the QT interval
such as Class IA and Ill antiarrhythm.ics increase
this risk and should be AVOIDED. These are
CONTRAINDICATIONS. Please refer to
package insert for additional drugs.
Cisapride labeling has always identified the
importance of judicious use in patients with
certain disease states for which the risk of
arrhythmia may be increased. Based on postmarketing reports, Janssen has identified and
specified disease states which cisapride should be
avoided or used precautiously.
CONTRAINDICATED in patients with
- hx prolonged QT interval
- hx ventricular arrhythmias
-RENAL FAILURE > due to electrolyte abnormalities
- CHF > due to electrolyte abnormalities/medications (ie. K
wasting diuretics)
- respiratory failure
- ischemic heart disease
..
- uncorrected electrolyte disorders (hypomagnesium/kalemia)
PRECAUTION in patients with
- COPD, apnea, advanced cancer
-severe dehydration, vomiting, malnutrition

This agent is not FDA INDICATED for use in
the pediatric and neonatal populations, however it
is sometimes utilized when alternatives are
limited. Serious adverse events including death
have been reported in infants and children treated
with cisapride. Several of these deaths were

cardiovascular in nature. Other serious event'
have been reported and are included in the
package insert.

)

Due to hepatic elimination it is necessary to
decrease the dose in patients with hepatic
insufficiency. The usual dose in healthy patients
is 10-20mg PO Q6H. It is recommended to
reduce the dose by half in these patients.
So, who can take this drug safely?
1.
Patient selection is KEY. Weigh the risks vs.
benefits of therapy as at times there are no reasonable
alternatives.
2.
Stay within recommended dosage guidelines and dose
adjust in hepatic impairment.
3.
Review medications thoroughly for possible drug-drug
interactions or drugs known to prolong QT interval.

The Department of Pharmacy will continue to
place cisapride information sheets as part of an
on-going education effort to recognize the
potential risks associated with cisapride usage.

Policy Update: Dextran-1 Test
Dose

)

Dextran-1 is a test dose utilized prior to the
administration of Dextran 40% or 70% to help
identify those patients at risk of allergic reactions.
To provide consistency in the management of
patients receiving IV dextran and a
standardization of practice and to assist in
preventing adverse effects from dextran, a
pharmacy policy has been developed. This policy
outlines the automatic administration of Dextran1 (Promit~ prior to all first time orders of IV
infusions of dextran or for additional doses of
dextran separated by more than 48 hours. This
will occur without a separate physician's order.
This pharmacy policy is an addition to the
Dextran-1 policy which presently exists in the
Patient Care Manual (PCM) and will go into
effect immediately.

Post-Operative Nausea and
Vomiting (PONV)
A variety of medications and techniques are

)
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available to prevent and manage patients who
experience PONV. An anesthesia subcommittee
has been working on an algorithm and guidelines
for potential use by ALL disciplines for
management of PONV. A review of the 5HT-3
medications, such as ondansetron (Zofran~, and
alternatives will be incorporated into the
recommendation along with specific populations.
Stay tuned for the final guidelines!

Nimbex, the NMB, is now
Floorstock!

)

On Tuesday, June 23, 1998, a housewide
conversion of vecuronium (Norcuron~) to
cisatracurium (Nimbex~) as the preferred
neuromuscular blocking agent, took place. The
switch of cisatracurium occurred due to less risk
of prolonged paralysis, decreased risk of drug
interactions, similar onset and duration of activity
and an overall decrease in cost to the institution
comparing equivalent doses of each medication
when administered in a bolus fashion.

.
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Conversion cards were provided with the
cisatracurium stock to assist staff with dosing
conversion for cisatracurium compared to
vecuronium. Besides the dosing, all other factors
regarding the administration, cautions and effects
of the neuromuscular blocking agents remain
constant.
Cisatracurium will be promoted as the frrst-line
agent for continuous infusion of a neuromuscular
blocking agent within the hospital. Vecuronium
will remain on the formulary for continuous
infusion for specific populations such as pediatrics
and those patients which may not be adequately
controlled with cisatracurium ie. patients who are
hypermetabolic, though usage is expected to be
limited.
The above recommendation was approved by the
Anesthesia Subcommittee of the Therapeutics
Committee.
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